An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease
α-Synuclein (α-Syn), a protein synthesized by neurons, as the major protein component of Lewy body inclusions, undoubtedly has a prominent role in the pathogenesis of Parkinson's Disease (PD). In an attempt to enable pre-symptomatic and definitive diagnosis, numerous attempts have been made to...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Royal Society of Chemistry
2014
|
| _version_ | 1826303665142497280 |
|---|---|
| author | Xu, Q Evetts, S Hu, M Talbot, K Wade-Martins, R Davis, J |
| author_facet | Xu, Q Evetts, S Hu, M Talbot, K Wade-Martins, R Davis, J |
| author_sort | Xu, Q |
| collection | OXFORD |
| description | α-Synuclein (α-Syn), a protein synthesized by neurons, as the major protein component of Lewy body inclusions, undoubtedly has a prominent role in the pathogenesis of Parkinson's Disease (PD). In an attempt to enable pre-symptomatic and definitive diagnosis, numerous attempts have been made to align assayed total α-Syn levels in serum (where there is a native presence) to PD disease status. Results have been conflicting. The status of circulating and potentially neuroprotective α-Syn autoantibodies in PD subjects is also unclear. In previous work we demonstrated that electrochemically assayed autoantibody levels were higher in PD patients compared to controls and, significantly, noted that this differentiation was most marked early in disease. Herein we report a robust (coefficient of variation 3.0%) single step and label free analysis of 90 subjects, including 60 PD patients, with a mean disease duration of 1.4 years and 29 control subjects. In this cross sectional cohort we observe a statistically significant (p < 0.05; Mann-Whitney U test) difference in autoantibody levels in PD patients versus controls, although there was no resolved scaling with symptomatic disease stage (p > 0.05; Kruskal-Wallis test). |
| first_indexed | 2024-03-07T06:06:09Z |
| format | Journal article |
| id | oxford-uuid:edeac0dc-14ef-4a8d-9deb-a50ef959a2f9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:06:09Z |
| publishDate | 2014 |
| publisher | Royal Society of Chemistry |
| record_format | dspace |
| spelling | oxford-uuid:edeac0dc-14ef-4a8d-9deb-a50ef959a2f92022-03-27T11:28:42ZAn impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:edeac0dc-14ef-4a8d-9deb-a50ef959a2f9EnglishSymplectic Elements at OxfordRoyal Society of Chemistry2014Xu, QEvetts, SHu, MTalbot, KWade-Martins, RDavis, Jα-Synuclein (α-Syn), a protein synthesized by neurons, as the major protein component of Lewy body inclusions, undoubtedly has a prominent role in the pathogenesis of Parkinson's Disease (PD). In an attempt to enable pre-symptomatic and definitive diagnosis, numerous attempts have been made to align assayed total α-Syn levels in serum (where there is a native presence) to PD disease status. Results have been conflicting. The status of circulating and potentially neuroprotective α-Syn autoantibodies in PD subjects is also unclear. In previous work we demonstrated that electrochemically assayed autoantibody levels were higher in PD patients compared to controls and, significantly, noted that this differentiation was most marked early in disease. Herein we report a robust (coefficient of variation 3.0%) single step and label free analysis of 90 subjects, including 60 PD patients, with a mean disease duration of 1.4 years and 29 control subjects. In this cross sectional cohort we observe a statistically significant (p < 0.05; Mann-Whitney U test) difference in autoantibody levels in PD patients versus controls, although there was no resolved scaling with symptomatic disease stage (p > 0.05; Kruskal-Wallis test). |
| spellingShingle | Xu, Q Evetts, S Hu, M Talbot, K Wade-Martins, R Davis, J An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title | An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title_full | An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title_fullStr | An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title_full_unstemmed | An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title_short | An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease |
| title_sort | impedimetric assay of alpha synuclein autoantibodies in early stage parkinson s disease |
| work_keys_str_mv | AT xuq animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT evettss animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT hum animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT talbotk animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT wademartinsr animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT davisj animpedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT xuq impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT evettss impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT hum impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT talbotk impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT wademartinsr impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease AT davisj impedimetricassayofalphasynucleinautoantibodiesinearlystageparkinsonsdisease |